依泽替米贝块B型肝炎病毒感染后，病毒进入肝细胞摄取

StephenW

依泽替米贝块B型肝炎病毒感染后，病毒进入肝细胞摄取
Antiviral Res. 2012 Dec 20. pii: S0166-3542(12)00288-4. doi: 10.1016/j.antiviral.2012.12.008. [Epub ahead of print]
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.Lucifora J, Esser K, Protzer U.
SourceInstitute of Virology, Technische Universität München / Helmholtz Zentrum München, Trogerstrasse, 30, 81675 Munich, Germany.

AbstractCurrent treatment of chronic Hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases. Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date. Recently, entry of the Hepatitis C virus (HCV) has been shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, has been shown to inhibit HCV infection. We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG-cells as a cell-culture infection model. Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we observed no effect when the HBV viral genome was transduced via an adenoviral vector. Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection

StephenW

抗病毒药物研究2012年12月20日。PII：S0166-3542（12）00288-4。 DOI：10.1016/j.antiviral.2012.12.008。[EPUB的提前打印]
依泽替米贝块B型肝炎病毒感染后，病毒进入肝细胞摄取。
埃塞尔Lucifora J，K，Protzer U.
源

病毒学研究所，慕尼黑工业大学/亥姆霍兹慕尼黑中心，Trogerstrasse，30，81675慕尼黑，德国。

摘要
目前治疗慢性乙型肝炎病毒（HBV）感染，主要是针对病毒在肝细胞中复制，只有在特殊情况下的固化。尽管他们的潜力，以提高治疗成功率，干扰肝炎的病原体HBV感染早期步骤是无药可用的日期。最近，已经显示出的C型肝炎病毒（HCV）的条目发生沿肝胆固醇的吸收途径和依泽替米贝的药物，阻止此脂质运输，已被证明抑制丙型肝炎病毒感染。我们这里使用分化HepaRG细胞作为细胞培养感染模型对HBV感染调查的影响的依泽替米贝。与依泽替米贝的治疗抑制肝内cccDNA建立和病毒复制标志物的表达与HBV病毒粒子感染细胞时，B型肝炎病毒基因组时，通过腺病毒载体转导的，而我们没有观察到效果。我们的数据表明，依泽替米贝的调节肝胆固醇的吸收，抑制HBV感染早期，依泽替米贝敏感脂质运输途径代表HBV感染抗病毒治疗的新目标

StephenW

Highlights亮点

► Ezetimibe is a drug known to block lipids transport. 依折麦布是一种药物，阻止脂质运输。
► We analyzed the effect of Ezetimibe on HBV infection using an in vitro model. 我们进行了依泽替米贝对乙肝病毒感染的影响,体外模型分析.
► Ezetimibe inhibits HBV infection at a post-entry step before formation of cccDNA.
HBV感染输入后,依泽替米贝抑制cccDNA形成.
► Ezetimibe rather targets a host factor than the virus itself. 依泽替米贝目标是一个宿主因素
而不是病毒本身.
► Our data suggest that HBV hijacks lipid transport pathways for its establishment.我们的数据表明乙肝病毒成立是劫持脂质的运输途径。

MP4

进口药品注册证号:H20060113
http://baike.baidu.com/view/1886393.htm

StephenW

回复 MP4 的帖子

依泽替米贝具有一些副作用（动脉壁增厚），但应该是值得做组合使用NUC的临床试验.

咬牙硬挺

惊喜啊